Mainz Biomed N.V. (MYNZ) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Mainz Biomed reported revenue of $537,080. Net income was -$16.2M (a -3018.3% net margin), or -$2.70 per diluted share. Gross margin was 72.6% and operating margin was -3005.0%. Operating activities generated -$11.0M of cash, leaving -$11.0M of free cash flow. At fiscal year end, Mainz Biomed held $5.3M in total assets against $4.7M in total liabilities.
Open the full interactive Mainz Biomed financials → Quarterly statements, key ratios, valuation history and price charts.
Mainz Biomed Key Stats
| Share Price | $1.12 |
|---|---|
| Market Cap | $20.0M |
| 52-Week Range | $0.32 – $3.56 |
| Shares Outstanding | 17.9 million (basic, 2026 Q2) |
Mainz Biomed Income Statement
| FY 2025 | |
|---|---|
| Revenue | $537,080 |
| Gross Profit | $389,792 |
| Operating Income | -$16.1M |
| Pre-Tax Income | -$16.2M |
| Net Income | -$16.2M |
| Diluted EPS | -$2.70 |
Mainz Biomed Quarterly Results
| 2026 Q1 | 2026 Q2 | |
|---|---|---|
| Net Income | -$5.1M | -$11.0M |
| Diluted EPS | -$0.43 | -$0.62 |
Mainz Biomed Balance Sheet
| FY 2025 | |
|---|---|
| Current Assets | $1.8M |
| Total Assets | $5.3M |
| Current Liabilities | $3.7M |
| Total Liabilities | $4.7M |
| Shareholders' Equity | $641,600 |
Mainz Biomed Cash Flow Statement
| FY 2025 | |
|---|---|
| Cash From Operations | -$11.0M |
| Cash From Investing | -$1.0M |
| Cash From Financing | $6.8M |
| Free Cash Flow | -$11.0M |
Figures from Mainz Biomed's 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Mainz Biomed financials page for every line item.
Mainz Biomed Company Profile
| Ticker | MYNZ |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Mainz |
| Fiscal Year End | December 31 |
| SEC Filer Category | Emerging growth company |
| SEC CIK | 0001874252 |
Frequently Asked Questions
What was Mainz Biomed's revenue in fiscal 2025?
Mainz Biomed (MYNZ) reported revenue of $537,080 for fiscal 2025.
What was Mainz Biomed's net income in fiscal 2025?
Mainz Biomed reported net income of -$16.2M for fiscal 2025.
What was Mainz Biomed's earnings per share (EPS) in fiscal 2025?
Mainz Biomed's diluted EPS was -$2.70 for fiscal 2025 (adjusted for any later stock splits).
How much free cash flow did Mainz Biomed generate in fiscal 2025?
Mainz Biomed generated -$11.0M of free cash flow in fiscal 2025.
How many shares of Mainz Biomed are outstanding?
Mainz Biomed reported a weighted average of 17.9 million basic shares outstanding in 2026 Q2.
What is Mainz Biomed's market cap?
Based on its latest closing price, Mainz Biomed (MYNZ) has a market capitalization of about $20.0M.
When does Mainz Biomed's fiscal year end?
Mainz Biomed's fiscal year end, as registered with the SEC, is December 31.
Where is Mainz Biomed headquartered?
Mainz Biomed lists its business address in Mainz in its SEC filings.